tetano
Editor, Senior Moderator
J Clin Med
. 2023 Jan 9;12(2):529.
doi: 10.3390/jcm12020529.
The SARS-COV-2 Seroprevalence among Oncology Patients
Mankgopo Kgatle[SUP] 1 2 [/SUP], Rajesh Das[SUP] 3 [/SUP], Ismaheel Lawal[SUP] 1 2 4 [/SUP], Tebatso Boshomane[SUP] 2 5 [/SUP], Kgomotso Mokoala[SUP] 2 4 [/SUP], Cattleya Gaspar[SUP] 6 [/SUP], Lydia Mbokazi[SUP] 6 [/SUP], Nonhlanhla Nkambule[SUP] 6 [/SUP], Veronique Gow[SUP] 7 [/SUP], Honest Ndlovu[SUP] 1 2 [/SUP], Yonwaba Mzizi[SUP] 1 2 [/SUP], Joseph Chalwe[SUP] 5 [/SUP], Jeaneth Diphofa[SUP] 7 [/SUP], Dinah Mokobodi[SUP] 7 [/SUP], Nobuhle Gxekwa[SUP] 2 8 [/SUP], Lusanda Zongo[SUP] 2 8 [/SUP], Tinashe Maphosa[SUP] 9 10 [/SUP], Mariza Vorster[SUP] 1 2 [/SUP], Sheynaz Bassa[SUP] 7 [/SUP], Amouda Venkatesan[SUP] 3 [/SUP], Richard Khanyile[SUP] 7 [/SUP], Yunus Munga[SUP] 1 [/SUP], Thomas Ebenhan[SUP] 1 4 11 [/SUP], Jan Rijn Zeevaart[SUP] 1 4 11 [/SUP], Mike Sathekge[SUP] 1 2 4 [/SUP]
Affiliations
Abstract
Patients with cancer are presumed to be vulnerable to an increased risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and severe clinical outcomes due to the immunocompromised state mediated by their underlying malignancies and therapy. The aim of this study was to estimate the SARS-CoV-2 seroprevalence, following second to fourth waves in solid tumour patients attending the Steve Biko Academic Hospital (SBAH) for diagnosis and treatment of cancer. We used the single-prick COVID-19 IgG/IgM Rapid Test Cassettes to detect SARS-CoV-2 IgG/IgM antibodies in 760 patients with solid tumours who were asymptomatic and who had never tested positive for coronavirus disease 2019 (COVID-19). Out of the 760 patients, 277 were male (36.4%), 483 were female (63.6%), and the mean age was 55 years (range 18-92). The estimated total seroprevalence was 33.2%. The seroprevalence status of the COVID-19 IgG/IgM antibodies rose significantly from the second wave (11.3%) to the third (67.38%) and then the fourth (69.81%) waves with roughly similar counts. A significant number of the seropositive patients were asymptomatic to COVID-19 (96%). There was a higher rate of seropositivity in cancer patients with hypertension (p < 0.05). Patients with breast, gynaecologic, and prostate cancers exhibited increased SARS-CoV-2 seropositivity. Although oncology patients may be susceptible to SARS-CoV-2 infection, our data indicate that these patients remained asymptomatic throughout various waves with an overall COVID-19 IgG/IgM antibody seropositivity of 33.16%, suggesting no risk of severe or fatal cases of COVID-19.
Keywords: COVID-19; IgG/IgM antibodies; SARS-CoV-2; South Africa; cancer.
. 2023 Jan 9;12(2):529.
doi: 10.3390/jcm12020529.
The SARS-COV-2 Seroprevalence among Oncology Patients
Mankgopo Kgatle[SUP] 1 2 [/SUP], Rajesh Das[SUP] 3 [/SUP], Ismaheel Lawal[SUP] 1 2 4 [/SUP], Tebatso Boshomane[SUP] 2 5 [/SUP], Kgomotso Mokoala[SUP] 2 4 [/SUP], Cattleya Gaspar[SUP] 6 [/SUP], Lydia Mbokazi[SUP] 6 [/SUP], Nonhlanhla Nkambule[SUP] 6 [/SUP], Veronique Gow[SUP] 7 [/SUP], Honest Ndlovu[SUP] 1 2 [/SUP], Yonwaba Mzizi[SUP] 1 2 [/SUP], Joseph Chalwe[SUP] 5 [/SUP], Jeaneth Diphofa[SUP] 7 [/SUP], Dinah Mokobodi[SUP] 7 [/SUP], Nobuhle Gxekwa[SUP] 2 8 [/SUP], Lusanda Zongo[SUP] 2 8 [/SUP], Tinashe Maphosa[SUP] 9 10 [/SUP], Mariza Vorster[SUP] 1 2 [/SUP], Sheynaz Bassa[SUP] 7 [/SUP], Amouda Venkatesan[SUP] 3 [/SUP], Richard Khanyile[SUP] 7 [/SUP], Yunus Munga[SUP] 1 [/SUP], Thomas Ebenhan[SUP] 1 4 11 [/SUP], Jan Rijn Zeevaart[SUP] 1 4 11 [/SUP], Mike Sathekge[SUP] 1 2 4 [/SUP]
Affiliations
- PMID: 36675457
- DOI: 10.3390/jcm12020529
Abstract
Patients with cancer are presumed to be vulnerable to an increased risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and severe clinical outcomes due to the immunocompromised state mediated by their underlying malignancies and therapy. The aim of this study was to estimate the SARS-CoV-2 seroprevalence, following second to fourth waves in solid tumour patients attending the Steve Biko Academic Hospital (SBAH) for diagnosis and treatment of cancer. We used the single-prick COVID-19 IgG/IgM Rapid Test Cassettes to detect SARS-CoV-2 IgG/IgM antibodies in 760 patients with solid tumours who were asymptomatic and who had never tested positive for coronavirus disease 2019 (COVID-19). Out of the 760 patients, 277 were male (36.4%), 483 were female (63.6%), and the mean age was 55 years (range 18-92). The estimated total seroprevalence was 33.2%. The seroprevalence status of the COVID-19 IgG/IgM antibodies rose significantly from the second wave (11.3%) to the third (67.38%) and then the fourth (69.81%) waves with roughly similar counts. A significant number of the seropositive patients were asymptomatic to COVID-19 (96%). There was a higher rate of seropositivity in cancer patients with hypertension (p < 0.05). Patients with breast, gynaecologic, and prostate cancers exhibited increased SARS-CoV-2 seropositivity. Although oncology patients may be susceptible to SARS-CoV-2 infection, our data indicate that these patients remained asymptomatic throughout various waves with an overall COVID-19 IgG/IgM antibody seropositivity of 33.16%, suggesting no risk of severe or fatal cases of COVID-19.
Keywords: COVID-19; IgG/IgM antibodies; SARS-CoV-2; South Africa; cancer.